Trial Profile
A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary) ; PT 2385 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; First in man
- Sponsors Peloton Therapeutics
- 10 Jan 2024 Planned End Date changed from 30 Nov 2023 to 30 Nov 2024.
- 18 Jul 2022 Planned End Date changed from 30 Nov 2022 to 30 Nov 2023.
- 23 Feb 2021 Planned End Date changed from 30 Nov 2021 to 30 Nov 2022.